Therapeutically Triggering an Innate Immune Response in a Target Tissue

Abstract

The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response.

1 - 8 . (canceled) 
     
     
         9 . The method according to  claim 36 , wherein the therapeutic vehicle further comprises one or more of: GMCSF, vitamin D, NOHA, alph1 antitrypsin, glutathione, an isoprenoid, or α-galactosylceramide. 
     
     
         10 - 19 . (canceled) 
     
     
         20 . The method according to  claim 36 , wherein therapeutic vehicle is administered at an administration site that is the skin or subcutaneous tissue. 
     
     
         21 - 24 . (canceled) 
     
     
         25 . The method according to  claim 36 , wherein the therapeutic vehicle is administered in a plurality of doses over a dosage duration, and the dosage duration is at least two weeks. 
     
     
         26 . The method according to  claim 25 , wherein the doses are administered subcutaneously every day, or every other day. 
     
     
         27 . (canceled) 
     
     
         28 . The method according to  claim 36 , wherein the patient is immunosuppressed or immunocompromised. 
     
     
         29 . The method according to  claim 36 , wherein the patient is a geriatric patient. 
     
     
         30 . The method according to  claim 36 , wherein the patient is a pediatric patient. 
     
     
         31 - 32 . (canceled) 
     
     
         33 . The method of  claim 36 , wherein the  Klebsiella  spp. is a  K. variicola  or  K. pneumonia  that is a pathogenic strain of  K. variicola  or  K. pneumonia.    
     
     
         34 - 35 . (canceled) 
     
     
         36 . A method of treating neutropenia in a human patient, comprising administering to the patient an effective amount of a therapeutic vehicle, comprising a whole killed or attenuated cell of a  Klebsiella  spp. 
     
     
         37 . The method of  claim 36 , wherein the neutropenia is caused by a myelosuppressive chemotherapy. 
     
     
         38 - 73 . (canceled)